←
Varun Mehra331 posts
Varun Mehra avatar

Varun Mehra

@docbmt

Haematologist @KingsCollegeNHS @myeloidkings #StemcellTransplantation #GVHD #MedicalMycology #loveToNetwork #BloodCancerResearch

◷ Joined September 2012▧ 23 Photos and videos
Jamie Blundell avatar
⟳ Varun Mehra retweeted
Jamie Blundell@jrblundell·Nov 11

How do cancers emerge from healthy tissue? In @Nature today: leukaemia evolving in yearly blood samples up to 15 yrs before AML. First driver by age 20; each new driver multiplies growth 2–3×. A remarkably simple set of mathematical rules recapitulate it. nature.com/articles/s41586-0…

NEJM avatar
⟳ Varun Mehra retweeted
NEJM@NEJM·Sep 2

In a randomized phase 2 trial involving adults with AML, azacitidine–venetoclax led to longer event-free survival than induction chemotherapy, with a lower risk of severe infection and hemorrhage. Full PARADIGM trial results: nej.md/4zJr1wV Editorial: Hypomethylating Agents plus Venetoclax as Compared with Intensive Chemotherapy in Patients with AML nej.md/4cgnBHO

Post attachment
GvHD Hub avatar
⟳ Varun Mehra retweeted
GvHD Hub@gvhd_hub·Jun 13

CONGRESS | #EHA2026 | PRESENTATION Johannes Schetelig presents findings from a randomized non-inferiority trial evaluating PTCy-100 vs ATLG-30 as #GvHD prophylaxis in allo-HSCT recipients from unrelated donors (N = 640). In the ITT population, the 2-year OS was 68% with PTCy-100 vs 75% with ATLG-30 (HR, 1.341; test for non-inferiority, p = 0.85; test for superiority, p = 0.051). The 2-year GRFS was 48% with PTCy-100 vs 40% with ATLG-30 (HR, 0.85; p = 0.16). The 2-year cumulative incidences of relapse were 26% and 31% (HR, 0.86), respectively. The 2-year NRM was 13% with PTCy-100 vs 7% with ATLG-30 (HR, 1.86; p = 0.02). Overall, confirmatory testing demonstrated that non-inferior survival with a 5% margin for PTCy-100 compared with ATLG-30 could not be shown. Follow our live feed for more updates: loom.ly/1BscQNI Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #GvHDsm #MedicalCongress @DKMS_SciMed

Post attachmentPost attachmentPost attachmentPost attachment
NEJM avatar
⟳ Varun Mehra retweeted
NEJM@NEJM·Jun 3

Original Article: Obexelimab for the Treatment of IgG4-Related Disease (phase 3 INDIGO trial results) nej.md/4fKYQG4 Editorial: Obexelimab and the Promise of Nondepleting B-Cell Therapy in IgG4-Related Disease nej.md/4fLybcd #EULAR2026 | @eular_org

Post attachmentPost attachment
Uriel Suárez avatar
⟳ Varun Mehra retweeted
Uriel Suárez@UsuarezMD·Apr 1

American Society of Hematology 2026 Guidelines for the Diagnosis and Management of Severe Acquired Aplastic Anemia | Blood Advances | American Society of Hematology ashpublications.org/bloodadv…

GvHD Hub avatar
⟳ Varun Mehra retweeted
GvHD Hub@gvhd_hub·Mar 23

CONGRESS | #EBMT26 | PRESENTATION Florent Malard reports final results from the phase III, multicenter, open-label ARES trial, evaluating MaaT013 as a third-line treatment option in patients with treatment-refractory GI-#aGvHD after systemic steroids and ruxolitinib (N = 66). ARES met its primary endpoint, with a Day 28 GI-ORR of 62%, exceeding the pre-established threshold of 22% (p < 0.0001). Most patients had Day 28 GI-CR (38%) or GI-VGPR (20%), with 5% experiencing GI-PR. The all-organ ORR at Day 28 was 64%, and GI-ORR was maintained in 47% at Day 56 and 44% at Month 3. With a median follow-up of 344.5 days, the median OS was not reached; OS was 54% at Month 12, and was higher among Day 28 responders vs non-responders (68% vs 28%). Follow our live feed for more updates: bit.ly/4lyVG9v Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #GvHDsm #MedNews #MedEd @TheEBMT @Florent_Malard @crsa_paris

Post attachmentPost attachmentPost attachmentPost attachment
Varun Mehra avatar
Varun Mehra@docbmt·29 Dec 2025

Time to step up and diligently apply regulatory framework for emerging novel therapeutic class (SoHO, Substances of Human Origin) in #HSCT and #GVHD. @Mohty_EBMT @TheEBMT nature.com/articles/s41409-0…

GvHD Hub avatar
⟳ Varun Mehra retweeted
GvHD Hub@gvhd_hub·7 Dec 2025

CONGRESS | #ASH25 | POSTER Everett Meyer presents data from a subgroup analysis of the phase III Precision-T trial of Orca-T versus tacrolimus + methotrexate (Tac/MTX) in patients with acute leukemia (N = 182). At 1 year, Orca-T demonstrated improved rates of chronic GvHD-free survival (78% vs 38%; p < 0.0001), OS (94% vs 83%; p = 0.045), GRFS (63% vs 31%; p < 0.0001), and NRM (13% vs 3.4%; p = 0.037) compared to Tac/MTX. Orca-T vs Tac/MTX showed improved clinical outcomes across patient subgroups with varied demographic and clinical features, including age, sex, donor type, and conditioning regimen. Follow our live feed for more updates: loom.ly/MbPzIiA Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website. #GvHD #GvHDsm #MedicalCongress @StanfordMed

Post attachmentPost attachmentPost attachmentPost attachment
Varun Mehra avatar
Varun Mehra@docbmt·24 Jul 2025

Inviting all HCPs involved in care for stem cell transplant patients to our 1st KHP Preceptorship Event (3/4th Sept 2025) for Transplant complications with #GVHD This is a limited space event, so book early.. Registration/program details below.. eventbrite.co.uk/e/graft-ver…

Post attachment